Literature DB >> 26053647

FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing.

Kenneth D Levy1, Victoria M Pratt2, Todd C Skaar1, Gail H Vance3, David A Flockhart1,4.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26053647      PMCID： PMC4719776          DOI： 10.1002/jcph.492

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  1 in total

1.  Revisiting oversight and regulation of molecular-based laboratory-developed tests: a position statement of the Association for Molecular Pathology.

Authors:  Andrea Ferreira-Gonzalez; Rajyasree Emmadi; Stephen P Day; Robert F Klees; Jennifer R Leib; Elaine Lyon; Jan A Nowak; Victoria M Pratt; Mary S Williams; Roger D Klein
Journal:  J Mol Diagn       Date:  2014-01       Impact factor: 5.568
  1 in total
  2 in total

1.  Integrating pharmacogenetic testing into primary care.

Authors:  Susanne B Haga
Journal:  Expert Rev Precis Med Drug Dev       Date:  2017-11-03

Review 2.  Precision medicine: from pharmacogenomics to pharmacoproteomics.

Authors:  Allison B Chambliss; Daniel W Chan
Journal:  Clin Proteomics       Date:  2016-09-26       Impact factor: 3.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.